157 related articles for article (PubMed ID: 35094294)
1. PEGylated nanoemulsions containing 1,2-distearoyl-sn-glycero-3-phosphoglycerol induced weakened accelerated blood clearance phenomenon.
Li Z; Gao X; Yan X; Deng Y; Ma H
Drug Deliv Transl Res; 2022 Oct; 12(10):2569-2579. PubMed ID: 35094294
[TBL] [Abstract][Full Text] [Related]
2. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
3. Accelerated Blood Clearance of Nanoemulsions Modified with PEG-Cholesterol and PEG-Phospholipid Derivatives in Rats: The Effect of PEG-Lipid Linkages and PEG Molecular Weights.
Liu M; Chu Y; Liu H; Su Y; Zhang Q; Jiao J; Liu M; Ding J; Liu M; Hu Y; Dai Y; Zhang R; Liu X; Deng Y; Song Y
Mol Pharm; 2020 Apr; 17(4):1059-1070. PubMed ID: 31860321
[TBL] [Abstract][Full Text] [Related]
4. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM.
Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W
J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169
[TBL] [Abstract][Full Text] [Related]
5. Effects of Uncleavable and Cleavable PEG-Lipids with Different Molecular Weights on Accelerated Blood Clearance of PEGylated Emulsions in Beagle Dogs.
Jiao J; Luo X; Wang C; Jiao X; Liu M; Liu X; Wei L; Deng Y; Song Y
AAPS PharmSciTech; 2020 Mar; 21(3):106. PubMed ID: 32185548
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration.
Su Y; Liu M; Liang K; Liu X; Song Y; Deng Y
AAPS PharmSciTech; 2018 Oct; 19(7):3210-3218. PubMed ID: 30187444
[TBL] [Abstract][Full Text] [Related]
7. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
Abu Lila AS; Kiwada H; Ishida T
J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
[TBL] [Abstract][Full Text] [Related]
8. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection.
Xu H; Ye F; Hu M; Yin P; Zhang W; Li Y; Yu X; Deng Y
Drug Deliv; 2015; 22(5):598-607. PubMed ID: 24524364
[TBL] [Abstract][Full Text] [Related]
9. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
10. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.
Ishida T; Ichihara M; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):243-50. PubMed ID: 17011060
[TBL] [Abstract][Full Text] [Related]
11. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
[TBL] [Abstract][Full Text] [Related]
12. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
13. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
Taguchi K; Urata Y; Anraku M; Watanabe H; Kadowaki D; Sakai H; Horinouchi H; Kobayashi K; Tsuchida E; Maruyama T; Otagiri M
Drug Metab Dispos; 2009 Nov; 37(11):2197-203. PubMed ID: 19679674
[TBL] [Abstract][Full Text] [Related]
14. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
[TBL] [Abstract][Full Text] [Related]
15. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.
Shimizu T; Ishida T; Kiwada H
Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937
[TBL] [Abstract][Full Text] [Related]
16. The Contribution of PEG Molecular Weights in PEGylated Emulsions to the Various Phases in the Accelerated Blood Clearance (ABC) Phenomenon in Rats.
Jiao J; Jiao X; Wang C; Wei L; Wang G; Deng Y; Song Y
AAPS PharmSciTech; 2020 Nov; 21(8):300. PubMed ID: 33140142
[TBL] [Abstract][Full Text] [Related]
17. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
[TBL] [Abstract][Full Text] [Related]
18. Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions.
Liu M; Zhao D; Yan N; Li J; Zhang H; Liu M; Tang X; Liu X; Deng Y; Song Y; Zhao X
Int J Pharm; 2022 Jan; 612():121365. PubMed ID: 34896215
[TBL] [Abstract][Full Text] [Related]
19. Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation.
Mostafa M; Elsadek NE; Emam SE; Ando H; Shimizu T; Abdelkader H; Ishima Y; Aly UF; Sarhan HA; Ishida T
Biol Pharm Bull; 2022; 45(1):129-135. PubMed ID: 34980774
[TBL] [Abstract][Full Text] [Related]
20. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
Abu Lila AS; Uehara Y; Ishida T; Kiwada H
J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
